FDA approved therapy for cholangiocarcinoma

U.S. regulators approved the drug Pemijatan (pemigatinib) for the treatment of adult patients with advanced cancer of the bile ducts – cholangiocarcinoma.

Cholangiocarcinoma is a rare malignant tumor of epithelial cells of the bile ducts. Pemijatan designed to treat tumors with a mutation in the gene FGFR2.

In support of the registration application of pamyatnaya was sent the results of clinical studies conducted among 107 patients. During testing, the overall response rate was 36%, with 2.8% of patients experienced a complete response, 33% partial response to therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]